Powys County, Wales (21 February, 2012) Hay-on-Wye based pharmaceutical packaging and clinical trials services specialist Brecon Pharmaceuticals announces the expansion of its storage and distribution capacity, with investment in a state-of-the-art, purpose-built facility in Pontypridd. The investment reflects Brecon Pharmaceuticals’ on-going commitment to continued excellence and to local economic growth.
Founded in 1980 and with premises based in the spectacular Wye Valley, Brecon Pharmaceuticals is one of the leading outsource service providers in the global pharmaceutical industry.
During the past 12 months, the company has defied the economic climate and continued to introduce the latest technologies and market-leading packaging solutions, attracting major contract wins. At the same time, Brecon has maintained its recruitment drive, which has seen an increase in its staff of over 10% in the same period.
Peter Belden, Managing Director comments: “The recent expansion reflects our commitment to innovation and quality through continuous investment in our people, facilities and equipment – a policy that has been rewarded with an almost tenfold increase in sales since 2002.”
Belden continues “The new site in Wales brings new opportunities for the area and the company is committed to recruiting local people from diverse background and providing them with training and expertise that are invaluable to personal development and to the development of the local economy.”
Brecon Pharmaceuticals and its sister company in the United States, Anderson Packaging, supports clients from the earliest stage of R&D through clinical trial and filing and on to commercialisation, packaging and supply. It works with a wide range of clients from small, ‘virtual’ companies through to the biggest global pharmaceutical organisations.
ENDS
Notes to Editor
About Brecon Pharmaceuticals
Founded in 1980, Brecon Pharmaceuticals is acknowledged as one of the leading outsourced-service providers in the global pharmaceutical industry. With unparalleled expertise in clinical trials supplies management and packing of solid dose forms into blisters, strips, wallets, bottles or sachets, backed by full in-house analytical services, Brecon is the preferred partner of the global pharmaceutical community. The company’s purpose-built facilities in Hay-on-Wye, Herefordshire, are the best-equipped and most modern in the UK.
Since 2006 Brecon has been a business of AmerisourceBergen Corporation. AmerisourceBergen is one of the world's largest pharmaceutical services companies serving the United States, Canada and selected global markets. Servicing both pharmaceutical manufacturers and healthcare providers in the pharmaceutical supply channel, the Company provides drug distribution and related services designed to reduce costs and improve patient outcomes. AmerisourceBergen's service solutions range from pharmacy automation and pharmaceutical packaging to reimbursement and pharmaceutical consulting services. With $80 billion in annual revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and employs approximately 10,000 people. AmerisourceBergen is ranked #27 on the Fortune 500 list.
Brecon works closely with its AmerisourceBergen sister company Anderson Packaging (Rockford, IL) to deliver harmonised services in Europe, the Americas and beyond.
For further information please visit www.breconpharm.com
For further press information please contact: Michelle Valentine, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire, CW4 8AA, United Kingdom Tel: + 44 1477 539539 Fax: +44 1477 539 540 E-mail: brecon@scottpr.com
Showing posts with label Pharmaceutical. Show all posts
Showing posts with label Pharmaceutical. Show all posts
Tuesday, 21 February 2012
Friday, 5 August 2011
CEO of Molecular Profiles Recognized as One of 100 Most Inspiring People in the Life Sciences Industry
(Nottingham, 5, August 2011) Molecular Profiles, a leading provider of pharmaceutical development services, announces that Nikin Patel, CEO, has been acknowledged as one of PharmaVOICE magazine’s top 100 most inspiring individuals in the life sciences industry. Dr. Patel has been recognized for his 13 years of dedicated commitment to advancing pharmaceutical technology that has seen him co-found a company infused with his own brand of innovative problem solving and new industry techniques. The PharmaVOICE 100 winners are nominated by the magazine’s readers, who identify the individuals they consider to have the most influence and positive impact on leadership, research and development, technology, creativity, marketing and business strategies.
“I feel incredibly honoured to be receiving this award,” said Dr.Patel. “But I have to add that it would not have been possible without my talented and inspiring colleagues. This award is very gratifying, and my team and I will continue the hard work to improve and add to our portfolio of services for the pharmaceutical industry.”
“I feel incredibly honoured to be receiving this award,” said Dr.Patel. “But I have to add that it would not have been possible without my talented and inspiring colleagues. This award is very gratifying, and my team and I will continue the hard work to improve and add to our portfolio of services for the pharmaceutical industry.”
Wednesday, 22 June 2011
Novozymes Biopharma to present on creating market opportunities through drug half-life extension at 2011 BIO Business Forum
Panel session and presentation will explore half-life extension technologies designed to overcome challenges associated with the therapeutic use of peptides and proteins.
NOTTINGHAM, UK - June 22, 2011 - Novozymes Biopharma, part of Novozymes A/S, the world leader in bioinnovation, today announced that it will be hosting a panel session within the manufacturing of biologics and drugs session track at the BIO Business Forum, during the 2011 BIO International Convention in Washington D.C, June 27-30. Svend Licht, senior director, Novozymes Biopharma will be moderating the session entitled 'Patient Compliance and market opportunities - the need for half-life extension' on Tuesday 28th June at 8.30am in room 156 AB, along with guest speakers from the world's leading drug development companies, including Pfizer, Sanofi, Teva Pharmaceuticals and Roche. The panel has been identified as leaders in their respective fields who use differing means of improving pharmacokinetics of biological drugs to offer enhanced benefits in the clinic.
NOTTINGHAM, UK - June 22, 2011 - Novozymes Biopharma, part of Novozymes A/S, the world leader in bioinnovation, today announced that it will be hosting a panel session within the manufacturing of biologics and drugs session track at the BIO Business Forum, during the 2011 BIO International Convention in Washington D.C, June 27-30. Svend Licht, senior director, Novozymes Biopharma will be moderating the session entitled 'Patient Compliance and market opportunities - the need for half-life extension' on Tuesday 28th June at 8.30am in room 156 AB, along with guest speakers from the world's leading drug development companies, including Pfizer, Sanofi, Teva Pharmaceuticals and Roche. The panel has been identified as leaders in their respective fields who use differing means of improving pharmacokinetics of biological drugs to offer enhanced benefits in the clinic.
Monday, 20 June 2011
Pfizer Selects Exco InTouch’s Novel eDiary Technologies to Initiate First Ever Patient-Centered Clinical Trial
(20 June, 2011) Exco InTouch, the leading provider of patient communication solutions for the pharmaceutical and healthcare sectors, has announced that its novel eDiary technologies have been selected by Pfizer, the world’s leading pharmaceutical company, as part of the first ever Participatory Patient-Centered (PPC) clinical trial. The pilot study will utilize Exco InTouch’s leading eDiary technologies to enable patients to participate regardless of location, age or proximity to site. Focusing on new Research on Electronic Monitoring of OAB Treatment Experience (REMOTE) Phase 4 for the treatment of overactive bladder, the study will mimic a previously completed trial in order to replicate the results and validate this novel approach.
In order to support the success of this patient-centered, field-based clinical research, Pfizer required a mobile technology platform offering an ease-of-use interface that provided accessibility particularly for older patients. With an estimated five billion cellphone users worldwide, cell phones make an ideal and accessible platform for patient engagement in clinical trials. As part of the revolutionary new approach piloted by the REMOTE study, patients will be empowered to participate remotely in the screening process through trials via the internet, participate in trials that due to location may not have previously been possible, actively manage their own trial and report results directly to a trial. As a result, researchers expect to save time and obtain more reliable, higher quality data through increased patient compliance and engagement, lower withdrawal rates and real-time data collection. The new approach will also eliminate the significant costs associated with the management and co-ordination of running multiple clinical sites.
In order to support the success of this patient-centered, field-based clinical research, Pfizer required a mobile technology platform offering an ease-of-use interface that provided accessibility particularly for older patients. With an estimated five billion cellphone users worldwide, cell phones make an ideal and accessible platform for patient engagement in clinical trials. As part of the revolutionary new approach piloted by the REMOTE study, patients will be empowered to participate remotely in the screening process through trials via the internet, participate in trials that due to location may not have previously been possible, actively manage their own trial and report results directly to a trial. As a result, researchers expect to save time and obtain more reliable, higher quality data through increased patient compliance and engagement, lower withdrawal rates and real-time data collection. The new approach will also eliminate the significant costs associated with the management and co-ordination of running multiple clinical sites.
Wednesday, 6 April 2011
Top 10 Global Pharmaceutical Company Selects Payne Security’s Tear Tape Solution to Protect Against Counterfeit Drugs
Payne Security, a leading supplier of brand protection solutions, has announced that one of its anti-counterfeiting solutions has been selected by a top ten global pharmaceutical company. The company selected Payne’s bespoke holographic Tear Tape technology to provide high security, protect its pharmaceutical products from counterfeiting and to provide tamper evidence. The overt technology was selected to provide a rapid, visual security solution that could provide instant reassurance to medical staff concerning the legitimacy and safety of the bottled drug product. The client revealed that counterfeiters, working together with corrupt health care workers and supply chain staff, were collecting empty product bottles, filling them with combinations of authentic and counterfeit product and then reintroducing the counterfeits into the supply chain. With increasing numbers of counterfeit drugs entering the market, the pharmaceutical company needed a rapidly deployable solution and approached Payne Security for specialist advice on the most appropriate solution to enable medical staff to instantly authenticate products through visual inspection.
Subscribe to:
Posts (Atom)